General and Oncological Department C, Chaim Sheba Medical Center-Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, 5265601, Tel Hashomer, Israel.
Department of Nutrition, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
J Gastrointest Surg. 2017 Dec;21(12):2009-2015. doi: 10.1007/s11605-017-3585-9. Epub 2017 Oct 2.
To evaluate the outcomes, weight loss predictors, and gastrointestinal symptoms of patients after laparoscopic sleeve gastrectomy (LSG).
The postoperative medical status of the patients was obtained retrospectively using a questionnaire and was compared to existing medical data before the surgery.
We included 201 candidates, 178 patients completed mean of 3 years of follow-up. Mean excess body weight loss (%EWL) was 65.14% ± 15.74 at 6 months, 78.53% ± 20.28 at 12 months, and 74.32% ± 23.92 at 3 years after LSG. Older age (P = 0.018), higher baseline BMI (P = 0.003), and higher number of medications (P < 0.001) were negative predictors for EWL%. Total weekly hours of physical activity was found to be a positive predictor for EWL% (P = 0.008). Remission rates of co-morbidities were 83.5% for dyslipidemia (P < 0.001), 65.8% for hypertension (P < 0.001), 62.1% for type 2 diabetes mellitus (T2DM) (P < 0.001), and 60.7% for gastroesophageal reflux (GERD) (P < 0.001). Late gastrointestinal symptoms were as follows: emesis in 25.9%, constipation in 24.7%, diarrhea in 4.5%, food intolerance in 22.5% and alopecia in 42.7% of the patients.
Our study shows LSG as a potential tool in achieving almost 75% of EWL% with significant remission of co-morbidities, along with various late gastrointestinal symptoms.
评估腹腔镜袖状胃切除术(LSG)后患者的治疗结果、体重减轻预测因素和胃肠道症状。
通过问卷调查回顾性地获取患者术后的医疗状况,并与手术前的现有医疗数据进行比较。
我们共纳入 201 名候选人,其中 178 名患者完成了平均 3 年的随访。LSG 术后 6 个月、12 个月和 3 年时的平均超重体重减轻率(%EWL)分别为 65.14%±15.74、78.53%±20.28 和 74.32%±23.92。年龄较大(P=0.018)、基线 BMI 较高(P=0.003)和服用药物种类较多(P<0.001)是 EWL%的负预测因素。每周体育活动总时间被发现是 EWL%的正预测因素(P=0.008)。合并症的缓解率分别为血脂异常 83.5%(P<0.001)、高血压 65.8%(P<0.001)、2 型糖尿病(T2DM)62.1%(P<0.001)和胃食管反流(GERD)60.7%(P<0.001)。晚期胃肠道症状如下:呕吐 25.9%、便秘 24.7%、腹泻 4.5%、食物不耐受 22.5%和脱发 42.7%。
我们的研究表明,LSG 可作为实现近 75%EWL%的潜在工具,同时显著缓解合并症,并伴有各种晚期胃肠道症状。